

**IND SWIFT LABORATORIES LTD.**


**Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160 101  
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2017  
CIN L24232CH1995PLC015553**

Particulars	(Rs. In Lacs)	
	Quarter Ended 30.06.2017	Quarter Ended 30.06.2016
	UnAudited	UnAudited
<b>Income from Operations:</b>		
Revenue from operations	16408.99	17992.94
Other Income	436.40	392.24
<b>Total Revenue</b>	<b>16845.39</b>	<b>18385.18</b>
<b>EXPENSES:</b>		
a Cost of Materials Consumed	9675.41	9268.86
b.Purchase of stock inTrade	0.00	88.73
c.( Increase) /decrease in FG,WIP & stock in trade	303.40	617.73
d. Staff cost	1845.53	1789.96
e.Finance Costs	2088.82	2478.90
f. Depreciation	2206.40	2188.40
g. Other expenditure	3019.91	3625.85
<b>TOTAL EXPENSES</b>	<b>19139.47</b>	<b>20058.44</b>
Profit(loss) before exceptional , extraordinary items and Tax	(2294.08)	(1673.26)
Exceptional Items	0.00	0.00
Profit(loss) before extraordinary items and Tax	(2294.08)	(1673.26)
Extraordinary items	0.00	0.00
Profit(loss) before Tax	(2294.08)	(1673.26)
<b>Tax Expenses :-</b>		
(1)Current Tax	0.00	0.00
Income Tax adjustment of Previous Year	0.00	0.00
Mat Credit Entitlement	0.00	0.00
(2)Deferred Tax	0.00	0.00
Profit (+)/ Loss (-) for the period from continuing operations	(2294.08)	(1673.26)
Profit (+)/ Loss (-) from discountinuing operations	0.00	0.00
Tax Expense of discountinuing operations	0.00	0.00
Profit (+)/ Loss (-) from discountinuing operations(after Tax)	0.00	0.00
Net Profit /( Loss) for the period	(2294.08)	(1673.26)
<b>Other Comprehensive Income</b>		
A) Items that will not be reclassified to P/L A/c	0.00	0.00
B) items that will be reclassified into P/L A/c	0.00	0.00
<b>Other Comprehensive Income / Loss for the period , net of Tax</b>	<b>0.00</b>	<b>0.00</b>
<b>Total Comprehensive Income for the Period</b>	<b>(2294.08)</b>	<b>(1673.26)</b>
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	4473.96	4473.96
Reserve excluding revaluation reserves	18,372.12	18,897.80
EPS (of Rs. 10/- each) (Not annualised)		
Basic	(5.13)	(4.08)
Diluted	(5.13)	(4.08)

**Notes: -**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th ,Sept 2017.
- The previous period figures have been re-grouped and re-arranged wherever necessary.
- The company has first time adopted IND AS with effect from 1st April 2017 ,with transition date of 1st April 2016.
- The unaudited standalone financial results have been prepared by the company in accordance with the companies (Indian accounting standards) rules ,2015 (IND AS) prescribed under section 133 of the companies act 2013 and other recognised accounting practices and policies to extent applicable
- The statement does not include IND-AS compliant results for the preceeding quarter and financial year ended 31.03.2017 as the same is not mandatory as per SEBI circuler date 05th July 2016.
- Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 30.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment of these deposits.
- There is no impact on Net profit /Loss, total Comprehensive Income or any other relevant financial item(s) due to transition from the previous Indian GAAP to IND AS, hence no comparison of the same has been provided.
- The Company is exclusively in the Pharmaceutical Business segment.

Place : Chandigarh  
Date: 14.09.2017

for Ind-Swift Laboratories Limited  
  
N R Munjal  
Vice Chairman cum Managing Director